Raymond Schuch

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Venues

Antimicrobial agents and chemotherapy

The Journal of infectious diseases

Microbiology spectrum

Applied and environmental microbiology

Contrafect Corporation

Temple University School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Contrafect Corporation Jul 01 2011

United States

Vice President of Research :: Microbiology

Rockefeller University Aug 01 2000 - Dec 15 2011

United States

Research Assistant Professor :: Bacterial Pathogenesis

Uniformed Services University of the Health Sciences Aug 01 1995 - Aug 01 2000

United States

Post Doctoral Fellow :: Microbiology and Immunology

Education History

Temple University School of Medicine Jul 15 1991 - Jul 15 1995

United States

PHD :: Microbiology and Immunology

Publications

Karen Sauve, Aubrey Watson, Jun T Oh, Steven Swift, Xavier Vila-Farres, Wessam Abdelhady, Yan Q Xiong, Dario LeHoux, Gary Woodnutt, Arnold S Bayer, Raymond Schuch
The Engineered Lysin, CF-370, is Active Against Antibiotic-Resistant Gram-Negative Pathogens In vitro and Synergizes with Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of infectious diseases (2024)
Karen Sauve, Aubrey Watson, Jun T Oh, Steven Swift, Xavier Vila-Farres, Wessam Abdelhady, Yan Q Xiong, Dario LeHoux, Gary Woodnutt, Arnold S Bayer, Raymond Schuch
The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of infectious diseases 230 (2) (2024)
Karen Sauve, Aubrey Watson, Jun T Oh, Steven Swift, Xavier Vila-Farres, Wessam Abdelhady, Yan Q Xiong, Dario LeHoux, Gary Woodnutt, Arnold S Bayer, Raymond Schuch
The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of infectious diseases 230 (2) (2024)
Jun Oh, Matthew Warner, Jane E Ambler, Raymond Schuch
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics. Microbiology spectrum (2023)
Xavier Vila-Farres, Karen Sauve, Jun Oh, Steven Swift, Boudewijn DeJonge, Jane E Ambler, Raymond Schuch
Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase. Microbiology spectrum (2023)
Aubin Souche, Camille Kolenda, Jordan Teoli, Raymond Schuch, Tristan Ferry, Frédéric Laurent, Jerome Josse
Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections. Antimicrobial agents and chemotherapy 66 (8) (2022)
Razieh Kebriaei, Kyle C Stamper, Katherine L Lev, Taylor Morrisette, Jacinda C Abdul-Mutakabbir, Raymond Schuch, Dario Lehoux, Michael Joseph Rybak
Exebacase in Addition to Daptomycin against MRSA. Antimicrobial agents and chemotherapy 65 (11) (2021)
Jun T Oh, Jane E Ambler, Cara Cassino, Raymond Schuch
Correction for Oh et al., "Development of a Broth Microdilution Method for Exebacase Susceptibility Testing". Antimicrobial agents and chemotherapy 65 (10) (2021)
Melissa J Karau, Suzannah M Schmidt-Malan, Jay Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel
Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis. Antimicrobial agents and chemotherapy 65 (6) (2021)
Tomefa E Asempa, Nicole A DeRosa, Cara Cassino, Dario Lehoux, Raymond Schuch, David P Nicolau
Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model. The Journal of antimicrobial chemotherapy 76 (10) (2021)
Aubrey Watson, Karen Sauve, Cara Cassino, Raymond Schuch
Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus. Antimicrobial agents and chemotherapy 64 (2) (2020)
Tomefa E Asempa, Kamilia Abdelraouf, Teresa Carabeo, Raymond Schuch, David P Nicolau
Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model. Antimicrobial agents and chemotherapy 64 (3) (2020)
Sonia U Shah, Yan Q Xiong, Wessam Abdelhady, James Iwaz, Youngju Pak, Raymond Schuch, Cara Cassino, Dario Lehoux, Arnold S Bayer
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography. Antimicrobial agents and chemotherapy 64 (7) (2020)
Raymond Schuch, Adam J Pelzek, Daniel C Nelson, Vincent A Fischetti
The PlyB Endolysin of Bacteriophage vB_BanS_Bcp1 Exhibits Broad-Spectrum Bactericidal Activity against Bacillus cereus Sensu Lato Isolates. Applied and environmental microbiology 85 (9) (2019)
Melissa J Karau, Suzannah M Schmidt-Malan, Qun Yan, Kerryl E Greenwood-Quaintance, Jayawant Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel
Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats. Antimicrobial agents and chemotherapy 63 (10) (2019)
Aubrey Watson, Jun Taek Oh, Karen Sauve, Patricia A Bradford, Cara Cassino, Raymond Schuch
Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis. Antimicrobial agents and chemotherapy 63 (10) (2019)
Chiara Indiani, Karen Sauve, Assaf Raz, Wessam Abdelhady, Yan Q Xiong, Cara Cassino, Arnold S Bayer, Raymond Schuch
The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis. Antimicrobial agents and chemotherapy 63 (4) (2019)
Jun Taek Oh, Cara Cassino, Raymond Schuch
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus. Antimicrobial agents and chemotherapy 63 (6) (2019)
Ryan D Heselpoth, Chad W Euler, Raymond Schuch, Vincent A Fischetti
Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria. Antimicrobial agents and chemotherapy 63 (6) (2019)

Raymond Schuch.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Raymond Schuch